SCHEMBL478164

SCHEMBL478164

Cn1nnc2cc(CBr)ccc21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.50
KEAP1 Q14145 3/20 0.48
SLC9A1 P19634 1/20 0.48
HPGD P15428 5/20 0.47
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 3/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
RAB9A P51151 4/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDO2 P48775 1/20 0.41
LMNA P02545 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL282111 0.86 SLC9A1 (0.48) HCAR3KEAP1SLC9A1HPGDKDM4E
SCHEMBL10287998 0.84 HCAR3 (0.51) HCAR3KEAP1SLC9A1HPGDKDM4E
SCHEMBL1939333 0.82 HCAR3 (0.54) HCAR3KEAP1SLC9A1HPGDKDM4E
SCHEMBL3330921 0.82 HCAR3 (0.50) HCAR3KEAP1SLC9A1HPGDKDM4E
SCHEMBL904701 0.82 HCAR3 (0.50) HCAR3KEAP1SLC9A1HPGDKDM4E
Hydrochloric Acid SCHEMBL23064161 0.81 HCAR3 (0.49) HCAR3KEAP1SLC9A1HPGDKDM4E
SCHEMBL13862926 0.81 HPGD (0.49) HCAR3KEAP1SLC9A1HPGDKDM4E
Hydrochloric Acid SCHEMBL27205663 0.81 HCAR3 (0.49) HCAR3KEAP1SLC9A1HPGDKDM4E
SCHEMBL12604538 0.79 HCAR3 (0.47) HCAR3KEAP1SLC9A1HPGDKDM4E
SCHEMBL9969405 0.79 POLB (0.48) HCAR3KEAP1SLC9A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106403-A1 NOVEL NRF2 ACTIVATOR AND USE THEREOF 나손사이언스(주) 2026-05-21 WO disclosed
EP-4271672-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-08 EP disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 US disclosed
WO-2022225941-A1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-10-27 WO disclosed
CN-110023292-B Apoptosis inhibitors 北京生命科学研究所 2022-10-04 CN disclosed
EP-3668872-B1 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS IMMUNOSTIMULANT TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL MYERS SQUIBB CO (US) 2022-02-23 EP disclosed
US-20210309647-A1 Apoptosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-10-07 US disclosed
US-11034680-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-06-15 US disclosed
EP-3484854-B1 APOPTOSIS INHIBITORS NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2021-01-20 EP disclosed
EP-2432776-B1 METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS UNIV LAVAL (CA) 2019-09-11 EP disclosed
WO-2009052126-A1 PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 WO disclosed
US-20090105275-A1 PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 US disclosed
US-20090023726-A1 Heterocyclylalkyl Derivatives as Novel Inhibitors of Histone Deacetylase JANSSEN-CILAG (FR) 2009-01-22 US disclosed
US-20080312230-A1 Organic Compounds NOVARTIS AG 2008-12-18 US disclosed
EP-1963317-A1 USE OF PYRROLO [2 , 3-B]PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN Novartis AG (CH) 2008-09-03 EP disclosed
US-20080114022-A1 (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease NOVARTIS AG (CH) 2008-05-15 US disclosed
EP-1761529-B1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS NOVARTIS AG (CH) 2007-11-14 EP disclosed
WO-2007068418-A1 USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN NOVARTIS AG (CH) 2007-06-21 WO disclosed
EP-1761529-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Novartis AG (CH) 2007-03-14 EP disclosed
WO-2005123731-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS NOVARTIS AG (CH) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105275-A1 PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE BACE1, BACE2, PSEN1 HCAR3 713/4885KEAP1 1921/4885SLC9A1 4583/4885
US-11725000-B2 Apoptosis inhibitors BAX, SDHA, SDHB HCAR3 2022/4885KEAP1 287/4885SLC9A1 1656/4885
US-20080114022-A1 (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease CCR1, CCL2, CCL11 HCAR3 52/4885KEAP1 2604/4885SLC9A1 1612/4885
US-11034680-B2 Apoptosis inhibitors BAX, SDHA, SDHB HCAR3 2022/4885KEAP1 287/4885SLC9A1 1656/4885
US-20080312230-A1 Organic Compounds OPRM1, OPRL1, OPRD1 HCAR3 308/4885KEAP1 2658/4885SLC9A1 1158/4885
US-20090023726-A1 Heterocyclylalkyl Derivatives as Novel Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 HCAR3 1382/4885KEAP1 1372/4885SLC9A1 2933/4885
US-20210309647-A1 Apoptosis Inhibitors BAX, SDHA, SDHB HCAR3 2022/4885KEAP1 287/4885SLC9A1 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.